Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2013

View Archived Issues

Respivert presents results for inhaled and intranasal formulations of RV-568

Merck & Co. synthesizes new CGRP receptor antagonists

E.U. funding supports work of SUPPRESSTEM consortium

SBIR grant awarded to Empire Genomics

Early clinical results reported for a novel cell-based gene therapy for melanoma

Amgen and Astellas Pharma establish strategic alliance for Japan

Valneva formed through merger of Vivalis and Intercell

Forest Laboratories presents phase III results for cariprazine in patients with schizophrenia

A novel variable rat model allows evaluation of the effects of ICP on optic neuropathies

Serum TSH levels as predictors of outcome in patients with severe sepsis

GSK and Tempero present novel HDAC9 inhibitors

FDA accepts POZEN's NDA for integrated aspirin therapy

Merck & Co. develops new S. aureus vaccines

Abbott receives license in Canada for RealTime High Risk HPV molecular diagnostic test

ThromboGenics licenses Eleven Biotherapeutics drug technology for diabetic eye diseases

EMA grants orphan drug designation to Sucampo's retinitis pigmentosa therapeutic

Genervon recruits for phase IIa ALS study following FDA clearance

Purdue Pharma patents novel Na(v)1.7 sodium channel blockers

Merck & Co. to return worldwide rights to novel antifungal candidate MK-3118

Janssen and Johnson & Johnson to fund collaboration for neurodegenerative diseases

Alethia and IBC Generium form strategic alliance

Chinese group prepares new PARP inhibitors

FDA approves two new GSK drugs, companion diagnostic for unresectable or metastatic melanoma

NeuroVive provides update on European phase III study of CicloMulsion in reperfusion injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...